Efficacy and Safety of Avatrombopag for Treating TCP in HBV-ACLF Patients Receiving ALSS Treatment

NCT05382013 ↗

Phase 4 Unknown 60 enrolled Third Affiliated Hospital, Sun Yat-Sen University

Non-randomizedParallel-groupOpen-labelPrevention

Summary

This study aims to investigate the efficacy and safety of avatrombopag for treating thrombocytopenia in hepatitis b virus related acute-on-chronic liver failure patients receiving artificial liver support system treatment.

Timeline

Start: 2022-04-27
Primary completion: 2024-02-29
Completion: 2024-04-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Avatrombopag	Small molecule	20 mg	Oral

Efficacy and Safety of Avatrombopag for Treating TCP in HBV-ACLF Patients Receiving ALSS Treatment

Summary

Timeline

Drugs

Indications